Rhizen is a pharmaceutical R&D company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders. Rhizen’s proprietary IP in these areas is aimed at generating first-best-early in class, compounds that are expected to offer novel therapeutic options for these significant unmet medical needs. Rhizen operates as a virtual company leveraging the best efficiencies through out sourcing to globally reputed laboratories while progressing from pre-clinical to clinical development.
Rhizen’s business strategy involves collaborating /licensing with large pharmaceuticals companies for late stage clinical development and global marketing while focusing on pushing the research pipeline through preclinical and early human clinical development.
